List view / Grid view
Abbott will feature new solutions to improve data management and automation at this year’s American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today’s laboratories will be the focal point of the Abbott exhibit.
13 July 2012 | By GlaxoSmithKline
Relvar™ and Breo™ proposed as brand names for FF/VI in EU and US...
12 July 2012 | By Daiichi Sankyo
Daiichi Sankyo has been approved for the Japanese Ministry of Economy, Trade and Industry’s production facility building grant...
12 July 2012 | By GlaxoSmithKline
GlaxoSmithKline has withdrawn a supplemental New Drug Application to the US FDA for Tykerb...
11 July 2012 | By Merck
Merck announced an update on the Phase III trial...
11 July 2012 | By GlaxoSmithKline
Data has been received from the Phase III Harmony 8 study...
11 July 2012 | By Eli Lilly and Company
Eli Lilly and Company announced negative clinical trial results...
As health care systems around the world face challenges such as labor shortages, increased regulation and budget constraints, they rely on technology to help manage the impact. To assist in addressing these challenges, today Abbott announced OneLab, a new, Web-based, integrated laboratory informatics solution.
Michael J. Valazza R.Ph., Vice President, Global Modified Release Technologies, Catalent Pharma Solutions, will be presenting on “Recent Advances in Oral Granules and Fixed Dose Tablet technologies, OptiMeltTM Solubility Enhancement Solutions, and Oral Disintegrating Tablet applications,” on Sunday, July 15th from 10:15AM -11:15AM as part of a releasing technology workshop…
11 July 2012 | By GlaxoSmithKline
Phase III SINGLE study results...
10 July 2012 | By kdm communications limited
Syrris has won a prestigious 2012 R&D 100 Award for Asia...
More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformité Européenne) for the Abbott ARCHITECT HbA1c…
10 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is concentrating on new business models...
10 July 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb announced on Friday, June 29, 2012, its intent to acquire Amylin...
Lonza, a world leader in gene expression and biopharmaceutical development of protein therapeutics, announced today the launch of the new GS Xceed™ Gene Expression System.
